BBHC
AXSM icon

Brown Brothers Harriman & Co’s Axsome Therapeutics AXSM Stock Holding History

Brown Brothers Harriman & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.2K Hold
62
– – ﹤0.01% 1343
2026
Q1 		$10.5K Buy
62
+8
+15% +$1.38K ﹤0.01% 1347
2025
Q4 		$9.86K Buy
+54
New +$7.54K ﹤0.01% 1345

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brown Brothers Harriman & Co's AXSM Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 62 shares worth $15.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1343.

Brown Brothers Harriman & Co first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Brown Brothers Harriman & Co held 62 shares of Axsome Therapeutics worth $15.2K as of Q2 2026.
  • Brown Brothers Harriman & Co left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1343 holding.
  • Brown Brothers Harriman & Co first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.